🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "huge turning point" in the effort against superbug strains of the pathogen, according to researchers.

A Global Public Health Issue

Gonorrhoea infections are escalating worldwide, with data suggesting more than 82 million infections annually. Especially elevated rates are reported in the African continent and countries within the WHO's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have hit a all-time high, while rates across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The authorization of fresh medications for gonorrhoea is an critical and opportune advancement in the face of rising global incidence, escalating drug resistance and the extremely scarce therapeutic options currently available.”

Medical experts are increasingly worried about the rise in drug-resistant strains. The global health body has designated it as a "priority pathogen". Ongoing monitoring revealed that the effectiveness of key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Treatment Options Secure Authorization

Zoliflodacin, marketed under the name Nuzolvence, was approved by the US FDA in December for use against gonorrhoea. This disease can lead to serious health problems, including infertility. Researchers hope that targeted use of this new drug will help delay the development of resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, was also approved in concurrent days. This medication, which is employed against urinary tract infections, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin emerged from a unique collaborative effort for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to see it through.

“This authorization marks a huge turning point in the treatment of superbug gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Testing Data and Worldwide Availability

As per results detailed in a prominent scientific publication, zoliflodacin cured more than 90% of genital gonorrhoea infections. This places it at an equal footing with the typical regimen, which uses an injection and a pill. The trial included nearly 1,000 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, GARDP has the authority to make available and distribute the drug in numerous regions with limited resources.

Doctors on the front lines have voiced optimism. The availability of a one-pill regimen such as this is seen as a "revolutionary step" for managing the epidemic. This is considered vital to reduce the burden of the infection for patients and to prevent the spread of untreatable gonorrhoea globally.